Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis

JAMA Oncology

Volumn 2, Issue 1, 2016, Pages 65-73

  Munhoz, Rodrigo R ^a,b   Pereira, Allan A L ^a,b   Sasse, André D ^c   Hoff, Paulo M ^a,b   Traina, Tiffany A ^d   Hudis, Clifford A ^d   Marques, Ricardo J ^e  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Research Institute   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FERTILITY PROMOTING AGENT; GONADORELIN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGONISTS; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; FEMALE; FERTILITY; FERTILITY PRESERVATION; HUMAN; INFERTILITY, FEMALE; MENSTRUATION; META ANALYSIS; METABOLISM; MIDDLE AGED; ODDS RATIO; OVARY; PATHOLOGY; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY RATE; PREMENOPAUSE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; FERTILITY; FERTILITY AGENTS, FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; MENSTRUATION; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; OVARY; PREGNANCY; PREGNANCY RATE; PREMENOPAUSE; RECEPTORS, LHRH; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973481521     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.3251     Document Type: Review

References (58)

1. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
3. Trivers KF, Fink AK, Partridge AH, et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist. 2014;19(8):814-822.
4. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(5):386-405.
5. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 2008;26(5):753-758.
6. Goldhirsch A, Gelber RD, Castiglione M; The International Breast Cancer Study Group. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol. 1990;1(3):183-188.
7. Valagussa P, Moliterni A, ZambettiM, Bonadonna G. Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res. 1993;127: 247-255.
8. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-1729.
9. Goodwin PJ, EnnisM, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17 (8):2365-2370.
10. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer. 2006;6(11):886-893.
11. Jeruss JS,Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9): 902-911.
12. Del Mastro L, VenturiniM, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997; 43(2):183-190.
13. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343 (15):1086-1094.
14. Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol. 2007;23(11):625-631.
15. KilWJ, Ahn SD, Shin SS, et al. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients. Breast Cancer Res Treat. 2006;96(3): 245-250
16. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7): 1045-1051.
17. VenturiniM, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97(23):1724-1733.
18. Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011; 29(9):1110-1116.
19. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8): 1575-1579.
20. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? the role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044-1054.
21. Ataya KM, McKanna JA,Weintraub AM, ClarkMR, LeMaireWJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985;45(8):3651-3656.
22. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990;61(6):861-865.
23. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52(2):365-372.
24. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106(3): 514-523.
25. Urruticoechea A, Arnedos M,Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2008;110(3):411-416.
26. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006;17(1):74-78.
27. Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53(4): 740-752.
28. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012; 30(5):533-538.
29. Gerber B, vonMinckwitz G, Stehle H, et al; German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334-2341.
30. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal womenwith breast cancer: a randomized trial. JAMA. 2011;306(3):269-276.
31. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117(3):561-567.
32. Badawy A, Elnashar A, El-AshryM, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694-697.
33. Han HS, Ro J, Lee KS, et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115(2):335-342.
34. Leonard RC, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman RE, et al The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol. 2010;28(15s):(suppl; abstr 590).
35. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013; 121(1):78-86.
36. Moore HCF, Unger JM, Phillips K-A, et al; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923-932.
37. Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30(3):667.
38. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011;(11):CD008018.
39. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906-14.e1, 4.
40. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122(3):803-811.
41. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40(5):675-683.
42. VitekWS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014;102(3): 808-815.e1.
43. Wang C, Chen M, Fu F, HuangM. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: ameta-analysis. PLoS One. 2013;8 (6):e66360.
44. Yang B, ShiW, Yang J, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: ameta-analysis of randomized controlled trials. Breast. 2013;22(2):150-157.
45. Loren AW, Mangu PB, Beck LN, et al; American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510.
46. Partridge AH, Gelber S, Peppercorn J, et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008;8(1): 65-69.
47. Falcone T, AttaranM, Bedaiwy MA, Goldberg JM. Ovarian function preservation in the cancer patient. Fertil Steril. 2004;81(2):243-257.
48. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
49. Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009;27(19):3192-3197.
50. Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol. 2014;35(1):59-61.
51. LambertiniM, Boni L, Michelotti A, et al. Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients. J Clin Oncol. 2014;32(26) (suppl):105.
52. Tham YL, Sexton K,Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30(2):126-132.
53. Davis AL, KlitusM,Mintzer DM. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer. 2005;6(5):421-424.
54. Lee S, KilWJ, Chun M, et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause. 2009;16(1):98-103.
55. Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22): 2053-2065.
56. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;34(5):632-640.
57. Parulekar WR, Day AG, Ottaway JA, et al; National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol. 2005;23(25): 6002-6008.
58. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26 (20):3324-3330.